HDL-C Levels and Cardiovascular Disease: More is not Always Better!

Author(s): Santiago Mc Loughlin, Gaston A. Rodriguez-Granillo

Journal Name: Recent Patents on Cardiovascular Drug Discovery
Continued as Recent Advances in Cardiovascular Drug Discovery

Volume 7 , Issue 2 , 2012


HMG-CoA reductase inhibitors have consistently demonstrated a relative risk reduction of death and myocardial infarction ranging between 29 and 35%. Nevertheless, in spite of significant improvement in prevention, cardiovascular disease remains the main cause of morbidity and mortality in industrialized countries. This significant residual risk observed in approximately 70% of patients under optimal anti-atherosclerotic therapies, warrants the exploration and development of alternative cardiovascular drugs. Specifically, HDL-C levels have been inversely correlated with the incidence of cardiovascular disease and an estimated 1 mg/dl higher HDL-C is associated with a 2% lower risk for men and a 3% lower risk for women. However, HDL-C-C pharmacological induced increases presented contradicting results regarding atherosclerotic development and in some cases increased cardiovascular mortality. In this review, we will focus on the structure and metabolism of HDL-C and patents related to HDL-C levels and cardiovascular disease along with the possible role of HDL-C increasing therapies in the future primary and secondary prevention of cardiovascular disease.

Keywords: ABCA1- Apo A1- cardiovascular disease, CETP inhibitors, dietary and lifestyle modifications, HDL-C, HDL-C metabolism - LXR agonists, niacin- recombinant HDL, PPAR modulators, HDL-C METABOLISM, Nascent HDL, ABCA1 Protein

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 18 June, 2012
Page: [121 - 133]
Pages: 13
DOI: 10.2174/157489012801227283
Price: $65

Article Metrics

PDF: 13